Literature DB >> 2984315

Encephalomyocarditis virus and diabetes mellitus: studies on virus mutants in susceptible and non-susceptible mice.

J P Kruppenbacher, T Mertens, H Müntefering, H J Eggers.   

Abstract

The so-called M-variant (especially subtype D) of encephalomyocarditis virus (EMCV) induces a diabetes-like syndrome in certain mouse strains which may serve as a model of insulin-dependent diabetes mellitus (IDDM) in man. The development and course of diabetes was influenced by a number of virus and host factors, among these being virus strain, virus dose, mouse strain, age, sex, and the host's immunological status. In a D-variant stock of EMCV, we found a virus plaque variant (PV 2) diabetogenic for DBA/2 mice, and at least one variant (PV 7) that did not affect carbohydrate metabolism. Although the diabetogenicity of PV 2 proved to be a genetically stable characteristic after further passages in vivo and in vitro, the incidence of diabetes varied somewhat (mean value 65% in 10-week-old DBA/2 mice infected with 10(5) p.f.u.). Both lower (10(1) or 10(3) p.f.u.) and higher (10(7) or 10(8) p.f.u.) virus doses led to a diminished incidence and severity of diabetes. In younger animals (5 weeks) transient hyperglycaemia often appeared, whereas in older animals (20 weeks) there was a higher rate of mortality. Histological examination of the islets of Langerhans in diabetes-susceptible (DBA/2) and resistant (C57BL/6) mice revealed that EMCV-induced hyperglycaemia appeared to develop in parallel to islet cell damage. Even in diabetic animals, some unaffected islets were regularly found. This study demonstrates that EMCV mutants may have completely different biological effects and produce diabetes only in special circumstances. Host factors play a significant role in the development of diabetes.

Entities:  

Mesh:

Year:  1985        PMID: 2984315     DOI: 10.1099/0022-1317-66-4-727

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  7 in total

Review 1.  Genome-virome interactions: examining the role of common viral infections in complex disease.

Authors:  Ellen F Foxman; Akiko Iwasaki
Journal:  Nat Rev Microbiol       Date:  2011-04       Impact factor: 60.633

2.  The poly(C) region affects progression of encephalomyocarditis virus infection in Langerhans' islets but not in the myocardium.

Authors:  A Zimmermann; A Botta; G Arnold; H J Eggers; B Nelsen-Salz
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

3.  The gamma interferon (IFN-gamma) mimetic peptide IFN-gamma (95-133) prevents encephalomyocarditis virus infection both in tissue culture and in mice.

Authors:  Mustafa G Mujtaba; Chintak B Patel; Ravi A Patel; Lawrence O Flowers; Marjorie A Burkhart; Lilian W Waiboci; James Martin; Mohammad I Haider; Chulbul M Ahmed; Howard M Johnson
Journal:  Clin Vaccine Immunol       Date:  2006-08

Review 4.  Enteroviruses in the pathogenesis of type 1 diabetes.

Authors:  Sisko Tauriainen; Sami Oikarinen; Maarit Oikarinen; Heikki Hyöty
Journal:  Semin Immunopathol       Date:  2010-04-28       Impact factor: 9.623

5.  Blocking by anti-idiotypic antibodies of monoclonal antibody mediated protection in mice against encephalomyocarditis virus induced diabetes and lethal disease.

Authors:  F Vlaspolder; T A Oosterlaken; M Harmsen; P W van Dijk; H Kievit; C A Kraaijeveld; H Snippe
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

6.  A wild-type porcine encephalomyocarditis virus containing a short poly(C) tract is pathogenic to mice, pigs, and cynomolgus macaques.

Authors:  Rebecca LaRue; Suzanne Myers; Laurie Brewer; Daniel P Shaw; Corrie Brown; Bruce S Seal; M Kariuki Njenga
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

7.  Outbred mice infected by an encephalomyocarditis virus variant: a model for studying chronic viral heart disease.

Authors:  J P Kruppenbacher; G Arnold; T Mertens; A Fischer; J Zimmermann; H J Eggers
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.